The Allergan BIOCELL Implants — Textured Shells Tied to Cancer and 33 Deaths

When Allergan announced a voluntary worldwide recall of its BIOCELL textured breast implants and tissue expanders on July 24, 2019 — at the request of the U.S. Food and Drug Administration — the gap between the product’s marketing and its documented harm was already a measurable oncologic toll: the FDA cited 573 unique cases of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) worldwide, of which 481 were attributable to Allergan devices, and 33 patient deaths, with 12 of the 13 deaths for which the implant maker was known confirmed to involve an Allergan implant. The agency’s analysis put the BIA-ALCL risk of BIOCELL macrotextured shells at roughly six times that of textured implants from other manufacturers then on the U.S. market. The implant had been sold as an ordinary reconstructive and cosmetic option; what it delivered, in a small but non-trivial fraction of recipients, was a lymphoma growing in the scar capsule around the device.

The harm was not a manufacturing defect in the conventional sense — it was the shell’s defining feature. BIOCELL was a macrotextured surface produced by a “salt-loss” process that pressed salt crystals into the silicone and dissolved them away, leaving a deeply pitted, high-surface-area shell originally marketed to anchor the implant and reduce capsular contracture. That same surface area is now the leading mechanistic suspect: it harbored more bacteria, sustained chronic biofilm and immune stimulation against the textured surface, and over years of low-grade inflammation appears to have driven T-cell transformation into ALCL in the periprosthetic capsule. The disease typically presented as a delayed seroma or mass years after implantation; caught early and treated by complete capsulectomy it was often curable, but advanced cases were lethal.

Regulators abroad moved first. France’s medicines agency, the ANSM, declined to renew the CE mark for Allergan’s macrotextured implants in December 2018 and in April 2019 became the first national regulator to ban macrotextured and polyurethane breast implants outright as a precaution. The FDA, which had publicly flagged a possible breast-implant/ALCL association as early as January 2011, did not force Allergan’s hand until July 2019 — by which point hundreds of thousands of the shells were already in patients’ bodies and would remain there, since neither the FDA nor Allergan recommended removing implants from asymptomatic women. As cumulative reporting matured, the case count climbed: by 2023 the FDA had documented on the order of 1,264 BIA-ALCL cases globally and 63 deaths, with roughly 85 percent of cases tied to Allergan textured devices. The BIOCELL recall became the modern textbook case of a device hazard that was rare, latent, and surface-intrinsic — and of a regulatory system that recognized the signal years before it acted on it.

The PIP breast implants — 300,000 Women Filled With Secret Industrial Silicone

When France’s medical-safety agency AFSSAPS suspended Poly Implant Prothèse’s silicone breast implants and forced the company into liquidation in March 2010, the gap between what founder Jean-Claude Mas had sold and what he had actually manufactured had been hidden for nearly a decade: since roughly 2001, PIP had quietly filled most of its implants with an in-house industrial-grade silicone — a gel built from chemicals such as Baysilone, Silopren, and Rhodorsil intended for fuel additives and rubber, not the medical-grade material on its certificates. The substitution cut the gel cost by close to 90 percent, from on the order of €35 per litre to roughly €5. The legend PIP traded on — a cut-price, CE-marked, third-largest implant maker in the world — was, for most of the prostheses it shipped, a fraud the company kept two sets of records to conceal.

The harm was mechanical and then systemic. The unapproved gel sat in shells that ruptured and leaked at rates independent reviews placed between 5 and 11 percent, against under 1 percent for approved implants — an elevation on the order of fivefold. When the shells failed, the industrial filler bled into surrounding tissue, provoking inflammation, lymph-node reactions, and repeat surgery. By the end of 2011, regulators were tracking roughly twenty cancer cases among PIP recipients and one death attributed to anaplastic large-cell lymphoma, though no causal link to the silicone was ever established. An estimated 300,000 women in some 65 countries carried the devices, many fitted for breast reconstruction after cancer.

Recall did not mean retrieval. Pulling the product and liquidating the maker left hundreds of thousands of devices inside bodies; on 23 December 2011 the French government went further than most and recommended that about 30,000 French women have the implants removed as a precaution. Criminal justice followed the bankruptcy: a Marseille court convicted Mas of aggravated fraud on 10 December 2013, sentencing him to four years in prison and a €75,000 fine and barring him from medicine and company management — upheld on appeal at Aix-en-Provence in May 2016. The deeper failure was the certification chain: notified body TÜV Rheinland had inspected PIP repeatedly between the late 1990s and 2010 without catching the swap, and in May 2021 the Paris Court of Appeal found it negligent and liable to victims. The scandal became the proximate fuel for the European Union’s 2017 Medical Device Regulation, the law written to close the door PIP had walked through.